News Sentiment

PSTV sentiment intelligence

Plus Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.74 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.5% over one week, -11.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -6.5% Price reacting lower
Trend fit Trend inactive -11.0% over four weeks
Fair value -86.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 40
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
Market source 15
Investing.com 5
TradingView 5
GlobeNewswire 3
simplywall.st 3
MT Newswires 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 15
Deals and strategy 2
Guidance 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Sahm Direct company coverage

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics, through its subsidiary CNSide Diagnostics, LLC, has signed a regional agreement with Medical Mutual to cover its CNSide® Cerebrospinal Fluid Assay for metastatic CNS cancer. This agreement expands the test's coverage to approximately 1.2 million people in Ohio

Tone
Positive 81/100
Event
Market update
Published
22 Jul 2026 00:40
Source
Sahm
Pluang Direct company coverage

Plus Therapeutics secures regional coverage for CNSide® assay in Ohio and Kentucky, expanding access to 1.2M people.

Plus Therapeutics' subsidiary, CNSide Diagnostics, has secured a regional agreement with Medical Mutual, extending coverage for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay to 1.2 million people in Ohio and Kentucky. This expansion brings the total national coverag

Tone
Positive 90/100
Event
Market update
Published
21 Jul 2026 12:10
Source
Pluang
Stock Titan Direct company coverage

Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases

Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a regional coverage agreement with Medical Mutual, effective July 1, 2026, which expands CNSide® cerebrospinal fluid assay coverage to an additional 1.2 million people in Ohio and Kentucky. This agreement incre

Tone
Positive 90/100
Event
Market update
Published
21 Jul 2026 11:30
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Plus Therapeutics partners with GTC on CSF diagnostic platform By Investing.com

Plus Therapeutics (NASDAQ: PSTV) has announced a partnership with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing technology into its CNSide cerebrospinal fluid assay platform. This collaboration aims to enhance the CNSide platform by enabling DNA and RN

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jul 2026 22:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Cancer guidelines broaden spinal-fluid analysis; Plus plans DNA, RNA

Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing into its CNSide cerebrospinal fluid assay platform. This partnership aims to enable comprehensive DNA and RNA profiling of hundreds of biomark

Tone
Positive 73/100
Event
Deals and strategy
Published
16 Jul 2026 11:10
Source
Stock Titan
Market source Direct company coverage

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Plus Therapeutics and Genomic Testing Cooperative (GTC) have partnered to integrate next-generation sequencing (NGS) into Plus's CNSide® cerebrospinal fluid (CSF) assay platform. This collaboration aims to provide comprehensive DNA and RNA profiling of hundreds of biomarkers from

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 10:12
Source
Market source
GuruFocus Direct company coverage

Plus Therapeutics (PSTV) Updates NCCN Guidelines for CNS Cancers

Plus Therapeutics (PSTV) announced updates to the NCCN Guidelines for Central Nervous System Cancers, focusing on improved diagnosis and assessment of leptomeningeal metastases. The company, a clinical-stage pharmaceutical firm with a market cap of $29.26 million, is developing t

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 14:41
Source
GuruFocus
Stock Titan Direct company coverage

Guidelines call for spinal-fluid checks every 4–8 weeks during therapy

Plus Therapeutics (PSTV) highlighted an update to the NCCN CNS Cancers Guidelines, which endorse cerebrospinal fluid (CSF) analysis and recommend CSF cytology follow-up every 4–8 weeks for leptomeningeal metastases (LM) patients undergoing intrathecal therapy. The company's CNSid

Tone
Positive 72/100
Event
Market update
Published
14 Jul 2026 11:41
Source
Stock Titan
Stock Titan Direct company coverage

Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting

Plus Therapeutics director Howard Clowes acquired 922 shares of common stock through the vesting of restricted stock units (RSUs) as part of his equity compensation. This transaction, filed on Form 4, increased his direct holdings to 1,981 common shares, with an additional 2,764

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock

PLUS Therapeutics director Ronald Asbury Andrews converted 922 Restricted Stock Units (RSUs) into 922 shares of common stock on July 1, 2026, as part of his compensation, at a stated price of $0.00 per share. Following this transaction, he directly holds 922 shares of common stoc

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

PLUS Therapeutics (PSTV) director converts RSUs into 922 common shares

PLUS Therapeutics director Kyle Guse exercised restricted stock units (RSUs) to acquire 922 shares of common stock at no cost. Following this transaction, Guse directly holds 922 common shares, with an additional 2,764 RSUs remaining outstanding, which will vest in quarterly inst

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity

PLUS THERAPEUTICS director Richard J. Hawkins reported an insider trading activity involving the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026. This transaction was compensation-related, with each RSU converting into one share of common stock at $0.00 per share. Af

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
Market source Direct company coverage

Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)

Plus Therapeutics, a healthcare company focusing on CNS cancers, announced it will rebrand as Cerenome and trade under the new Nasdaq ticker CNSY starting August 3, 2026. The company also reaffirmed its 2026 guidance, highlighting increased insurance coverage for its CNSide diagn

Tone
Positive 67/100
Event
Guidance
Published
30 Jun 2026 12:39
Source
Market source
Investing.com Direct company coverage

Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY

Plus Therapeutics (NASDAQ:PSTV) will rebrand as Cerenome and change its ticker symbol to CNSY, starting August 3, 2026. The company, which specializes in central nervous system cancers, currently trades at $4.29 with a market capitalization of $29.7 million, despite a 66.5% year-

Tone
Positive 64/100
Event
Market update
Published
30 Jun 2026 11:39
Source
Investing.com
Stock Titan Direct company coverage

Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3

Plus Therapeutics (Nasdaq: PSTV) announced a rebranding to Cerenome with its ticker changing to CNSY, effective August 3, 2026. The company affirmed its 2026 milestone guidance, providing updates on REYOBIQ clinical trials, commercial expansion of its CNSide diagnostic platform,

Tone
Positive 77/100
Event
Guidance
Published
30 Jun 2026 11:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Plus Therapeutics is rebranding to Cerenome and will trade under the new Nasdaq ticker CNSY starting August 3, 2026. This change reflects the company's integrated CNS oncology platform, combining therapeutics, diagnostics, and data analytics. The company also affirmed its 2026 gu

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 11:39
Source
GlobeNewswire
TradingView Direct company coverage

Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV

This article displays the title "Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV" and provides an overview of the company on TradingView. It indicates that the market is closed and no trades have occurred for PSTV. The content primarily focuses on navigation, m

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 04:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV

This article provides financial data, specifically the "Price to sales forward," for PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV). It appears to be a financial snapshot from TradingView, offering details within a larger platform context. The content presents the "Period," "Value," "Cha

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:10
Source
TradingView
GlobeNewswire Direct company coverage

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Plus Therapeutics (Nasdaq: PSTV) announced it will host a business update call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. Management will discuss the CNSide® diagnostic launch, its integrated development plan for Reyobiq, and provide details on its CNS onco

Tone
Positive 70/100
Event
Market update
Published
27 Jun 2026 06:09
Source
GlobeNewswire
TradingView Direct company coverage

Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1)

This article provides an overview of Plus Therapeutics, Inc. (DUS:XMP1) financials, analyst estimates, and key stock performance metrics. It includes details on past earnings, revenue, net income, and future earnings estimates. The article also covers the stock's highest and lowe

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 02:40
Source
TradingView
TradingView Direct company coverage

Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1)

This article provides an overview of Plus Therapeutics, Inc. (XMP1) stock on GETTEX, including its current price, historical performance, analyst forecasts, and key financial metrics. It details income statement, balance sheet, and cash flow data, as well as upcoming earnings rep

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 15:39
Source
TradingView
Market source Direct company coverage

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Inc., through its subsidiary CNSide Diagnostics, LLC, has announced a national agreement with Elevance Health, Inc. This agreement, effective May 1, 2026, extends coverage for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximat

Tone
Positive 82/100
Event
Market update
Published
25 Jun 2026 23:11
Source
Market source